...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Primary Endpoint Results for Phase 3 BETonMACE Cardio Outcomes Trial were Announced September 30th ****Detailed Trial Data to be Presented at AHA Late Breaking Session Nov 16th & Company Webcast Nov 18th******

Free
Message: Patient Years & MACE rate Question

As Bear suggested, I am taking back the claim that 1,925 patients were left on Phase 3 trial.  I verified this with IR at Resverlogix.  They said that the 1,900 patients were DOSED so far...and that includes the Phase 2 patients as well.

My heart felt apologies. 

I was being conservative.  However, if anything, the writing up of the 1,925 patients to say, 2,200 total patients, makes the RRR for RVX that much robust.  Number of additional patient years with a 250 to 265 MACE total, makes the MACE from placebo that much bigger part of the total MACE.

 

Share
New Message
Please login to post a reply